Dong Sung Bio Pharm.Co.,Ltd.

KOSE:A002210 Stock Report

Market Cap: ₩63.6b

Dong Sung Bio Pharm.Co.Ltd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Won-gyun Na

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure3.2yrs

Recent management updates

Recent updates


CEO

Won-gyun Na (38 yo)

less than a year
Tenure

Mr. Won-gyun Na is CEO of Dong Sung Bio Pharm.Co. Ltd. from October 14, 2024.Mr. Won-gyun Na is Chairman of Dong Sung Bio Pharm.Co. Ltd. and is its Director since March 28, 2022.


Board Members

NamePositionTenureCompensationOwnership
Won-gyun Na
Chairman & CEO3.2yrsno datano data
Yong-min Won
Inside Directorless than a yearno datano data
Young-ryeol Lee
Independent Outside Director3.2yrsno datano data
3.2yrs
Average Tenure
38yo
Average Age

Experienced Board: A002210's board of directors are considered experienced (3.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 05:52
End of Day Share Price 2025/05/07 00:00
Earnings2011/12/31
Annual Earnings2011/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dong Sung Bio Pharm.Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sang-Hun LeeiM Securities
Choongwoo SeoSK Securities Co., Ltd.
sangyun LeeYuanta Securities Korea Co., Ltd.